Molecure S.A.
ISIN: PLONCTH00011 | Ticker: MOC | LEI: 2594003L11V38ZCVKZ09
Country: Poland
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases.
We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the VIB Gent, the University of Michigan, and more recently the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science.
Our most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis that is Phase II ready. Molecure expects to start a Phase II trial in patients with sarcoidosis in 2023.
2012
Served areaWorldwide
HeadquartersŻwirki I Wigury 101, 02-089 Warszawa – Poland
| Line item in (pln) | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 157,187,479.00 | N/A | 151,590,713.00 | 138,061,151.00 |
| Noncurrent Assets | N/A | 23,417,477.00 | N/A | 35,648,863.00 | 63,071,854.00 |
| Property Plant And Equipment | N/A | 2,663,506.00 | N/A | 3,988,463.00 | 5,218,051.00 |
| Intangible Assets Other Than Goodwill | N/A | 69,797.00 | N/A | 101,249.00 | 256,296.00 |
| Deferred Tax Assets | N/A | 0.00 | N/A | 0.00 | 0.00 |
| Current Assets | N/A | 133,770,002.00 | N/A | 115,941,850.00 | 74,989,297.00 |
| Trade And Other Current Receivables | N/A | 1,264,649.00 | N/A | 1,448,258.00 | 2,505,985.00 |
| Current Tax Assets Current | N/A | 12,003,029.00 | N/A | 12,454,277.00 | 6,865,527.00 |
| Cash and cash equivalents | 34,039,071.00 | 120,502,324.00 | 120,502,324.00 | 102,039,315.00 | 65,617,785.00 |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | 133,770,002.00 | N/A | 115,941,850.00 | 74,989,297.00 |
| Equity And Liabilities | N/A | 157,187,479.00 | N/A | 151,590,713.00 | 138,061,151.00 |
| Equity | 79,129,831.00 | 147,092,666.00 | 147,092,666.00 | 141,143,534.00 | 126,447,925.00 |
| Issued Capital | N/A | 136,000.00 | N/A | 139,516.00 | 140,300.00 |
| Retained Earnings | N/A | 53,518,617.00 | N/A | 39,882,297.00 | 24,618,600.00 |
| Share Premium | N/A | 89,434,346.00 | N/A | 98,153,259.00 | 101,197,609.00 |
| Other Reserves | N/A | 4,003,703.00 | N/A | 2,968,462.00 | 491,416.00 |
| Equity Attributable To Owners Of Parent | N/A | 147,092,666.00 | N/A | 141,143,534.00 | 126,447,925.00 |
| Liabilities | N/A | 10,094,813.00 | N/A | 10,447,179.00 | 11,613,226.00 |
| Noncurrent Liabilities | N/A | 3,481,673.00 | N/A | 4,282,230.00 | 4,633,635.00 |
| Noncurrent Provisions | N/A | 75,705.00 | N/A | 72,432.00 | 83,905.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 75,705.00 | N/A | 72,432.00 | 83,905.00 |
| Noncurrent Payables | N/A | N/A | N/A | 0.00 | 205,084.00 |
| Accruals Classified As Noncurrent | N/A | 0.00 | N/A | 10,933.00 | 141,936.00 |
| Deferred Tax Liabilities | N/A | 0.00 | N/A | 0.00 | 0.00 |
| Current Liabilities | N/A | 6,613,140.00 | N/A | 6,164,949.00 | 6,979,591.00 |
| Current Provisions | N/A | 871,366.00 | N/A | 1,091,496.00 | 753,757.00 |
| Current Provisions For Employee Benefits | N/A | 503,946.00 | N/A | 765,219.00 | 640,757.00 |
| Other Shortterm Provisions | N/A | 367,420.00 | N/A | 326,277.00 | 113,000.00 |
| Trade And Other Current Payables | N/A | 816,915.00 | N/A | 1,985,478.00 | 2,822,807.00 |
| Current Deferred Income Other Than Current Contract Liabilities | N/A | N/A | N/A | 358,263.00 | 37,207.00 |
| Other Current Payables | N/A | 752,830.00 | N/A | 919,719.00 | 1,160,475.00 |
| Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | 6,613,140.00 | N/A | 6,164,949.00 | 6,979,591.00 |
| Line item in (pln) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 124,909,869.00 | 1,167,910.00 | 1,613,238.00 |
| Other Income | 3,696.00 | 292,435.00 | 25,031.00 |
| Raw Materials And Consumables Used | 98,556.00 | 184,088.00 | 1,102,999.00 |
| Services Expense | 4,276,561.00 | 4,026,200.00 | 6,028,241.00 |
| Wages And Salaries | 6,834,252.00 | 3,925,052.00 | 6,217,557.00 |
| Social Security Contributions | 1,098,055.00 | 1,043,222.00 | 1,670,629.00 |
| Expense From Sharebased Payment Transactions With Employees | 0.00 | 2,835,000.00 | 441,600.00 |
| Depreciation And Amortisation Expense | 218,366.00 | 299,817.00 | 1,313,155.00 |
| Tax Expense Other Than Income Tax Expense | 155,904.00 | 26,670.00 | 31,211.00 |
| Other Expense By Nature | 221,043.00 | 295,193.00 | 1,288,712.00 |
| Profit Loss From Operating Activities | 73,704,195.00 | -13,764,299.00 | -16,987,402.00 |
| Finance Income | 889,653.00 | 786,589.00 | 1,911,223.00 |
| Finance Costs | 939,716.00 | 658,609.00 | 187,518.00 |
| Profit Loss Before Tax | 73,654,132.00 | -13,636,319.00 | -15,263,697.00 |
| Income Tax Expense Continuing Operations | 5,691,500.00 | 0.00 | 0.00 |
| Profit Loss From Continuing Operations | 67,962,632.00 | -13,636,319.00 | -15,263,697.00 |
| Profit Loss From Discontinued Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | 67,962,632.00 | -13,636,319.00 | -15,263,697.00 |
| Profit Loss Attributable To Owners Of Parent | 67,962,632.00 | -13,636,319.00 | -15,263,697.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
| Line item in (pln) | 01.01.2021 | 02.01.2020 | 01.01.2022 | 02.01.2021 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | 67,962,632.00 | N/A | -13,636,319.00 | N/A | -15,263,697.00 |
| Adjustments For Reconcile Profit Loss | -10,527,155.00 | N/A | 139,902.00 | N/A | 5,050,314.00 |
| Adjustments For Depreciation And Amortisation Expense | 218,366.00 | N/A | 299,817.00 | N/A | 1,313,155.00 |
| Adjustments For Provisions | 517,296.00 | N/A | 216,858.00 | N/A | -326,267.00 |
| Adjustments For Sharebased Payments | 0.00 | N/A | 2,835,000.00 | N/A | 441,600.00 |
| Other Adjustments For Noncash Items | 203.00 | N/A | 13,507.00 | N/A | 9,467.00 |
| Adjustments For Reconcile Profit Loss | -10,527,155.00 | N/A | 139,902.00 | N/A | 5,050,314.00 |
| Cash Flows From Used In Operations | 57,435,477.00 | N/A | -13,496,417.00 | N/A | -10,213,383.00 |
| Cash Flows From Used In Operating Activities | 57,435,477.00 | N/A | -13,496,417.00 | N/A | -10,213,383.00 |
| Cash Flows From Used In Investing Activities | 8,579,410.00 | N/A | -18,823,380.00 | N/A | -33,585,507.00 |
| Proceeds From Issuing Shares | 0.00 | N/A | 4,838,680.00 | N/A | 117,020.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 1,435,569.00 | N/A | -728,186.00 | N/A | -272,474.00 |
| Proceeds From Government Grants Classified As Financing Activities | 21,852,452.00 | N/A | 8,238,898.00 | N/A | 6,861,144.00 |
| Interest Paid Classified As Financing Activities | -31,483.00 | N/A | -51,024.00 | N/A | -126,722.00 |
| Cash Flows From Used In Financing Activities | 20,448,366.00 | N/A | 13,856,788.00 | N/A | 7,377,360.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 86,463,253.00 | N/A | -18,463,009.00 | N/A | -36,421,530.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 0.00 | N/A | 0.00 | N/A | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | 86,463,253.00 | N/A | -18,463,009.00 | N/A | -36,421,530.00 |
| Cash and cash equivalents | 120,502,324.00 | 34,039,071.00 | 102,039,315.00 | 120,502,324.00 | 65,617,785.00 |
Please note that some sums might not add up.
PLONCTH00011
LEI2594003L11V38ZCVKZ09
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.